Pathophysiology and drug therapy of tardive dyskinesia: Current concepts and future perspectives

Drugs of Today

Volumn 39, Issue 1, 2003, Pages 19-49

  Kulkari, Shrinivas K ^a   Naidu, Pattipati S ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOMORPHINE; BENZODIAZEPINE; BROMOCRIPTINE; CALCIUM; CHOLINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FREE RADICAL; GANGLIOSIDE GM1; GLUTAMIC ACID; HALOPERIDOL; METHYLDOPA; METOCLOPRAMIDE; NEUROLEPTIC AGENT; NITRIC OXIDE; OLANZAPINE; PHENOTHIAZINE; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; PIMOZIDE; RESERPINE; RISPERIDONE; SELEGILINE; SERTINDOLE; TETRABENAZINE; UBIDECARENONE; UNINDEXED DRUG;

AKATHISIA; ATHETOSIS; BEHAVIOR DISORDER; CHOLINERGIC SYSTEM; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; INVOLUNTARY MOVEMENT; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSONISM; PHARMACOGENETICS; PREVALENCE; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DYSKINESIA, DRUG-INDUCED; HUMANS; SCHIZOPHRENIA;

EID: 0037234476     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.1.799430     Document Type: Review

References (226)

1. Raja, M. Tardive dystonia: Prevalence, risk factors and comparison with tardive dyskinesia in a population of two hundred acute psychiatric in patients. Eur Arch Psychiatry Cli Neurosci 1995, 245: 145-51.
2. Sachdev, P., Saharov, T., Cathcart, S. The preventive role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia. Biol Psychiat 1999, 46: 1672-81.
3. Jeste, D.V., Calliguri, M.P. Tardive dyskinesia. Schrizophr Bull 1993, 19: 303-15.
4. Jeste, D.V., Lacro, J.P., Baily, A., Rockwell, E., Harris, J.M., Calliguri, M.P. Lower incidence of tardive dyskinesia with rispiridone compared with haloperidol in older patients. J Am Geriatr Soc 1999, 47: 716-9.
5. Casey, D.E. Tardive dyskinesia: Pathophysiology. In: Psychopharmacology. The Fourth of Generation Progress. Floyd, E., Bloom, Kupfer, D.J. (Eds.). Raven Press: New York 1995, 1497-502.
6. Schonecker, M. Ein eigentumliches syndrom in oralen bereich bei megaphen applikation. Nervenartz 1957, 28: 35.
7. Kruse, W. Persistent muscular restlessness after phenothiazine treatment: Report of three cases. Am J Psychiat 1960, 117: 152-3.
8. Hunter, R., Earl, J.C., Thornicroff, S. An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proc Royal Soc Med 1964, 57: 758-62.
9. Faurbye, A., Rasch, P.J., Petersen, P.V. et al. Neurological symptoms in pharmacotherapy in psychosis. Acta Psychiat Scand 1964, 40: 10.
10. Haag, H., Ruther, E., Hippius, H. Tardive Dyskinesia. Hogrefe and Huber: Seattle 1992.
11. American Psychiatric Association. Tardive Dyskinesia: A task force report. American Psychiatric Sssociation, Washington, D.C. 1991.
12. Tarsy, D. History and definition of tardive dyskinesia. Clin Neuropharmacol 1983, 6: 91-9.
13. Casey, D.E., Rabins, P. Tardive dyskinesia as life-threatening illness. Am J Psychiat 1978, 135: 486-8.
14. Kane, J.M. Tardive dyskinesia: Epidemiological and clinical presentation. In: Psychopharmacology: The Fourth Generation of Progress. Bloom, F.E., Kupfer, D.J. (Eds.). Raven Press: New York 1995, 1485-96.
15. Andreassen, O.A., Jorgessen, H.A. Neurotoxicity associated with neuroleptic induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000, 61: 525-41.
16. Yassa, R., Jeste, D.V. Gender differences in tardive dyskinesia: A critical review if the literature. Schizophr Bull 1992, 18: 701-15.
17. Kane. J.M. Tardive dyskinesia. In: Neuropsychiatric Movement Disorders. Jeste, D.V., Wyatt, R.J. (Eds.). American Psychiatric Press: Washington, D.C. 1984, 68-95.
18. Morgenstern, H., Galzer, W.M. Identifying risk-factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch Gen Psychiat 1993, 15: 723-33.
19. Sachdev, P.S. The current status of tardive dyskinesia. Austr NZ J Psychiatry 2000, 34: 355-69.
20. Kulkarni, S.K., Naidu, P.S. Tardive dyskinesia: An update. Drugs of Today 2001, 37: 97-119.
21. Burke, R.E., Kangh, U.J., Jankovic, J. Tardive akathisia: An analysis of clinical features and response to open therapeutic trials. Mov Disord 1989, 4: 157-75.
22. Awouters, F., Niemegeers, C.J.E., Jansen, P.A.J. Tardive dyskinesia: Etiological and therapeutic aspects. Pharmacopsychit 1990, 23: 33-7.
23. Weinhold, P., Wegner, J.T., Kane, J.M. Familial occurrence of tardive dyskinesia. J Clin Psychiat 1981, 42: 165-6.
24. Riestschel, M., Krauss, H., Muller, D.J. et al. Dopamine D3 receptor variant in tardive dyskinesia. Eur Arch Psychiat Clin Neurosci 2000, 250: 31-5.
25. Tamminga, C.A., Dale, J.M., Goodman, L., Kaneda, H., Kaneda, N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains. Psychopharmacol 1990, 102: 474-8.
26. Belmaker, R.H., Bannet, J., Brecher-Fride, E., Yanai, J., Ebstein, R.P. The effect of haloperidol feeding on dopamine receptor number in ten mouse strains. Clin Genet 1994, 19: 353-6.
27. Youssef, H., Lyster, G., Yousef, F. Famillial psychosis and vulnerability to tardive dyskinesia. Int Clin Psychopharmacol 1989, 4: 323-8.
28. Waddington, J.L., Yousssef, H.A. The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree. Br J Psychiat 1988, 153: 376-81.
29. th World congress on psychiatric genetics, Bonn, Germany. Am J Med Genet 1998, 81: 527.
30. Hori, H., Ohmori, O., Shinkai, T., Kojima, H., Nakamura, J. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001, 105: 774-8.
31. 3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenia patients. Mol Psychiat 1997, 2: 139-45.
32. 3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiat 1999, 4: 247-53.
33. 3 dopamine receptor gene is associated with hyperactivity in mice. Pro Natl Acad Sci USA 1996, 93: 1945-9.
34. 3 receptor and risk for tardive dyskinesia in schizophrenia patients. Int J Neuropsychopharmacol 2000, 3: 61-6.
35. gly alleles to susceptibility. Psychopharmacol 2000, 152: 408-13.
36. 2C receptor is a prominent serotonin receptor in basal ganglia: Evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis. J Neurochem 1997, 69: 1449-58.
37. Segman, R.H., Heresco-Levy, U., Finkel, B. et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiat 2001, 6: 225-9.
38. Bates, G.D.L., Lopes, O., Van Woerkom, A.E., Kloverza, L., Waring, R. Tardive dyskinesia: Probing abnormal metabolism with promethazine. Act Psychiat Scand 1999, 99: 294-9.
39. Cholerton, S., Daly, A.K., Idle, J.R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends in Pharmacological Sci 1992, 13: 434-8.
40. Armstrong, M., Daly, A.K., Blennerhasset, R., Ferrier, N., Idle, J.R. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiat 1997, 170: 23-6.
41. 3 receptor gene polymorphisms on abnormal involuntary movements in schizophrenia. Biol Psychiat 2002, 51: 261-3.
42. Kimura, T., Shono, M., Yokota, S. et al. Apolipoprotein E 4 and tardive dyskinesia in a Japanese population. J Psychiat Res 2000, 34: 329-32.
43. Zhang, A., Zhang, X., Hou, G., Sha, W., Reynolds, G.P. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiat Res 2002, 36: 317-24.
44. Muller, D.J., Schulze, T.G., Knapp, M. et al. Familial occurrence of tardive dyskinesia. Acta Psychiat Scan 2001, 104: 375-9.
45. Egan, M.F., Apud, J., Wyatt, R.J. Treatment of tardive dyskinesia. Schizophr Bull 1997, 23: 583-609.
46. Klawans, Jr. H.L., Ilahi, M.M., Shenker, D. Theoretical implications of the use of L-dopa parkinsonism. Acta Neurol Scand 1970, 46: 409-41.
47. Mackay, A.V.P. Neurology 2: Movement disorders. In: Butterworth's International Medical reviews. Marsden, C.D., Fahn, S. (Eds.). Butterworth Scientific: London 1982, 249-62.
48. Fibiger, H.C., Lloiyd, K.G. Neurobiological substrates of tardive dyskinesia: The GABA hypothesis. Trends Neurosci 1984, 7: 462-4.
49. Nielsen, E.B., Lyon, M. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenithixol) in rats. Psychopharmacol 1978, 59: 85-9.
50. Gunne, L.M., Haggstrom, J.E., Sjoquist, B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984, 309: 347-9.
51. Johansson, P. Methyl azo methanol (MAM)induced brain lesion and oral dyskinesia in rats. Psychopharmacol 1990, 100: 72-6.
52. Delfs, J.M., Ellison, G.D., Mercugliano, M., Chesselet, M.F. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp Neurol 1995, 133: 175-88.
53. Thaker, G.K., Tammminga, C.A., Alphs, L.D., Lafferman, J., Ferraro, T.N., Hare, T.A. Brain-aminobutyric acid abnormality in tardive dyskinesia. Arch Gen Psychiat 1987, 44: 522-9.
54. Gunne. L.M., Bachus, S.E., Gale, K. Oral movements induced by interference with nigral GABA neurotransmission: Relationship to tardive dyskinesias. Exp Neurol 1988, 100: 459-69.
55. Tamminga, C.A., Crayton, J.W., Chase, T.N. Improvement in tardive dyskinesia after muscimol therapy. Arch Gen Psychiat 1979, 36: 595-9.
56. Kaneda, H., Shirakawa, O., Dale, J., Goodman, L., Bachus, S.E., Tamminga, C.A. Coadministration of progabide inhibits haloperidol-induced oral dyskinesia in rats. Eur J Pharmacol 1992, 212: 43-9.
57. Gao, X.M., Kakigi, T., Friedman, M.B., Tamminga, C.A. Tigabine inhibits haloperidol-induced oral dyskinesias in rats. J Neurol Transm 1994, 95: 63-9.
58. Seiler, N., Grauffel, C., Elands, J. et al. Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin. Pharmacol Biochem Behav 1995, 50:181-9.
59. Andersson, U., Haggstrom, J.E., Levin, E.D., Bobdesson, U., Valverius, M., Gunne, L.M. Reduced glutamate decarboxylase activity in the subthalamic nucleus in-patients with tardive dyskinesia. Mov Disord 1989, 4: 37-46.
60. Korsagard, S., Casey, D.E., Gerlach, J. Effect of γ-vinyl-GABA in tardive dyskinesia. Psychiatry Res 1983, 20: 22-6.
61. Thaker, G.K., Nguyen, J.A., Strauss, M.E., Jacobson, R., Kaup, B.A., Tamminga, C.A. Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy. Am J Psychiat 1990, 147: 445-51.
62. Cadet, J.L., Lohr, J.B. Possible involvement of free radicals in neuroleptic-induced movement disorders: Evidence from treatment of tardive dyskinesia with vitamin E. Ann New York Acad Sci 1989, 4: 37-46.
63. McGeer, E.G., McGeer, P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kinic acids. Nature 1976, 263: 517-9.
64. De Keyser, K. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin Neuropharmacol 1991, 14: 562-5.
65. Gunne, L.M., Andren, P.E. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: A glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 1993, 16: 90-5.
66. Moghaddam, B., Bunney, B.S. Depolarization inactivation of dopamine neurons: Terminal release characteristics. Synapse 1993, 14: 195-200.
67. See, R.E., Lynch, A.M. Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. Neuroreport 1995, 6: 1795-8.
68. Dawson, Jr. R., Beal, M.F., Bondy, S.C., Di Monte, D.A., Isom, G.E. Excitotoxins, aging, and environmental neurotoxins: Implications for understanding human neurodegenerative diseases. Toxicol Appl Pharmacol 1995, 134: 1-17.
69. Novelli, A., Reilly, J.A., Lysko, P.G., Henneberry, R.C. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988, 451: 205-12.
70. Dubinsky, J.M., Kristal, B.S., Elizondo-Fournier, M. et al. An obligatory role for oxygen in the early stages of glutamate-induced, delayed neuronal death. Neurosci 1995, 15: 7071-8.
71. Coyle, J.T., Puttfarcken, P. Oxidative stress glutamate and neurodegenerative disorders. Science 1993, 262: 689-95.
72. Patel, M., Day, B.J., Crapo, J.D. et al. Requirement for superoxide in excitotoxic cell death. Neuron 1996, 16: 345-55.
73. Volterra, A., Trotti, D., Tromba, C. et al., Glutamate uptake inhibition by free oxygen radicals in rat cortical astrocytes. J Neurosci 1994, 14: 2924-36.
74. Rothman, S.M., Olney, J.W. Excitotoxicity and the NMDA receptor - still lethal after eight years. TINS 1995, 18: 57-8.
75. Andreassen, O.A., Jorgensen, H.A. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. Psychopharmacol 1994, 116: 517-22.
76. Kharlmov, A., Guidotti, A., Costa, E., Hayes, R., Armstrong, D. Semisynthetic sphingolipids prevent protein kinase C translocation and neuronal damage in the perifocal area following a photochemically induced thrombotic brain cortical lesion. J Neurosci 1993, 13: 2483-94.
77. Andreassen, O.A., Aamo, T.O., Jorgensen, H.A. Inhibition by memantine of the development of persistent oral dyskinesias induced by long term haloperidol treatment of rats. Br J Pharmacol 1996, 119: 751-7.
78. Chung, Y.C., Eun, H.B., Kim, Y.H. Effect of MK-801 on the prevention and treatment of vacuous chewing in rats. XXI CINP congress, Glasgow 1998, Abst.
79. Naidu, P.S., Kulkarni, S.K. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): Possible involvement of calcium and nitric oxide. Behav Pharmacol 2001, 12: 209-16.
80. Yamamoto, B.K., Cooperman. M.A. Chronic treatment with antipsychotic drugs differentially affects concentrations of striatal glutamate and dopamine. CNP Annual Meeting, San Juan, Puerto Rico, 1992.
81. Yamamoto, B.K., Davy, S. Dopaminergic modulation of glutamate release in striatum as measured by micridialysis. J Neurochem 1992, 58: 1736-42.
82. Miller, R., Chourinard, G. Loss of striatal cholinergic neurons as a basis for tardive dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiat 1993, 34: 713-38.
83. Turski, L., Ikonomidou, C. Towards an understanding of tardive dyskinesia: Chronic haloperidol enhances NMDA toxicity in mouse striatum. Soc Neurosci Abst 1995, 21: 1744.
84. Tsai, G., Goff, D.C., Chang, R.W., Flood, J., Bare, L., Coyle, J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiat 1998, 155: 1207-13.
85. Meshul, C.K., Stallbaumer, R.K., Taylor, B., Janowsky, A. Haloperidol-induced morphological changes in striatum are associated with glutamate synapse. Brain Res 1994, 648: 181-95.
86. See, R.E., Lynch, A.M. Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats. Eur J Pharmacol 1996, 308: 279-82.
87. Fletcher, E.J., MacDonald, J.F. Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurons. Eur J Pharmacol 1993, 235: 291-5.
88. McCoy, L., Richfield, E.K. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci Lett 1996, 213: 137-41.
89. Fitzgerald, L.W., Deutch, A.Y., Gasic., G., Heinemann, S.F., Nestlet, E.J. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 1995, 15: 2453-61.
90. Meador-Woodruff, J.H., King, R.E., Damask, S.P., Bovenkerk, K.A. Differential regulation of hippocampal AMPA and kinate receptor subunit expression by haloperidol and clozapine. Mol Psychiat 1996, 1: 41-53.
91. Yamamoto, B.K., Cooperman. M.A. Chronic haloperidol alters substantia nigra GABA and extracellular glutamate in the striatum. Soc Neurosci Abstr 1993, 19: 1623.
92. Yamamoto, B.K., Cooperman. M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994, 14: 4159-66.
93. Lidsky, T.I., Yablonsky-Alter, E., Zuck., L.G., Banerjee, S.P. Antipsychotic drug effects on glutamatergic activity. Brain Res 1997, 764: 46-52.
94. Lidsky, T.I., Yablonsky-Alter, E., Zuck, L., Banerjee, S.P. Anti-glutamatergic effects of clozapine. Neurosci Lett 1993, 163: 155-8.
95. Jorgensen, H.A., Andreasen, O.A. Memantine inhibits the development of haloperidolinduced persistent oral movements. Soc Neurosci Abstr 1995, 470.
96. Bergmann-Erb, D., Engberg, I., Ten Bruggencate, G. Biogenicamines facilitate N-methylDL-aspartate responses in the guinea-pig neocortex in vitro. Plfugers Arch Suppl 1988, 411: R127.
97. Cepeda, C., Colwell, C.S., Itri, J.N., Chandler, S.H., Levine, M.S. Dopaminergic modulation of NMDA-induced hole cell currents in neostriatal neurones in slice: Contribution of calcium conductance. J Neurophysiol 1998, 79: 82-94.
98. 1 dopaminergic proteinkinase/phosphatase cascade in rat neostriatal neurons. Neurone 1995, 14: 385-97.
99. 1 dopamine receptors through a cAMP/proteinkinase A-dependent mechanism. Nature 1990, 348: 239-42.
100. Levine, M.S., De Fazio, T., Espinosa de los Monteros, A., De Vellis, J. Dopamine modulation of NMDA-induced calcium transients in fetal neocortical cultures and dissociated neostriatal neurons. Soc Neursci Abstr 1997, 23: 1190.
101. Schwartz, B.L., Fay-McCarthy, M., Kendrik, K., Rosse, R.B. Effects of a calcium channel antagonist, on cognitive function in schizophrenia patients with tardive dyskinesia. Clin Neuropharmacol 1997, 20: 364-70.
102. Chouza, C., Romero, S., De Medina, O. et al. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations. Eur Neurol 1987, 27 (Suppl.1): 59-67.
103. Bredt, D.S., Snyder, S.H. Isolation of nitric oxide synthase, a calmodulin requiring enzyme. Proc Natl Acad Sci USA 1990, 87: 682-5.
104. Garthwaite, J., Garthwaite, G., Palmer, R.M.J., Moncada, S. NMDA receptor activation induces nitric oxide synthase from arginine in rat brain slices. Eur J Pharmacol 1989, 172: 413-6.
105. Knowles, R.J., Palacios, M., Palmer, R.M.J., Moncada, S. Formation of nitric oxide from, Larginine in the central nervous system. A transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci USA 1989, 86: 5159-62.
106. Garthwaite, J., Charles, S.L., Chess Williams, R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggest role as intercellular messenger, in the brain. Nature 1988, 336: 385-8.
107. Schuman, E.M., Madison, D.V. Nitric oxide and synaptic function. Ann Rev Neurosci 1994, 17: 153-83.
108. Getting, S.J., Segieth, J., Ahmad, S., Biggs, C.S., Whitton, P.S. Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo. Brain Res 1996, 717: 196-9.
109. 3H] dopamine from striatal slices. Neuroreport 1992, 3: 409-12.
110. Sandor, N.T., Brassai, A., Puskas, A., Lendai, B. Role of nitric oxide in modulating neurotransmitter release rat striatum. Brain Res Bull 1995, 36: 483-6.
111. Segovia, G., Mora, F. Role of nitric oxide in modulating the release of dopamine, glutamate, and GABA in striatum of the freely moving rat. Brain Res 1998, 45: 275-9.
112. Ohno, M., Arai, I., Watanbe, S. N-methyl-Daspartate stimulates dopamine release through nitric oxide formation in the nucleus accumbens of rats. Brain Res 1995, 699: 332-5.
113. Zhu, X.Z., Luo, L.G. Effect of nitropruside (nitric oxide) on endogenous dopamine release from rat striatal slices. J Neurochem 1992, 59: 932-5.
114. 3H] dopamine uptake. Brain Res 1994, 641: 83-91.
115. Huerta, V.C., Zarate, C.B., Guerrerao, M.U., Velasco, A.F. Nitric oxide involvement in regulating the dopamine transport in the striatal region of rat brain. Neurochem Int 1997, 31: 607-16.
116. Kiss, J.P., Hennings, E.C.P., Zsilla, G., Vizi, E.S. A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum. Neurochem Int 1999, 34: 345-50.
117. Cadet, J.L., Lohr, J.B., Jeste, D.V. Free radicals and tardive dyskinesia. Trends Neurosci 1986, 9: 107-8.
118. Cohen, B.M., Zubenko, G.S. In vivo effects of psychotropic agents on the physical pertest of cell membranes in the rat brain. Psychopharmacol 1985, 86: 365-8.
119. Nishikimi, M. Generation of superoxide anion in the reaction of tetrahydropterins with molecular oxygen. Arch Bioche Biophys 1975, 166: 273-9.
120. Mishra, H.P., Fridovich, I. The generation of superoxide radical during the autooxidation of ferrodoxins. J Biol Chem 1971, 246: 6886-90.
121. Cadet, J.L., Kahler, L.A. Free radial mechanism in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 1994, 18: 457-767.
122. Sachdev, P.S. Drug-induced movement disorders in institutionalized adults with mental retardation: Clinical characteristics and risk factors. Aust NZ J Psychiat 1992, 26: 242-8.
123. Lohr, J.B., Kuczenski, R., Bracha, H.S., Moir, M., Jeste, D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiat 1990, 28: 535-9.
124. Lohr, J.B., Lavori, P. Whither vitamin E and tardive dyskinesia? Biol Psychiat 1998, 43: 861-2.
125. Adler, L.A., Edson, R., Lavori, P. et al. Long term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiat 1998, 43: 868-72.
126. Creese, G., Burt, D., Synder, S.I.L. Dopamine receptor binding and pharmacological potencies and antischizophrenic drugs. Science 1976, 192: 481-3.
127. Elkashef, A.M., Wyatt, R.J. Tardive dyskinesia: Possible involvement of free radical and treatment with vitamin E. Schizo Bull 1999, 25: 731-40.
128. Fleckenstein, A.E., Metzger, R.R., Beyeler, M.L., Gibb, J.W., Hanson, G.R. Oxygen radicals diminish dopamine transporter function in rat striatum. Eur J Pharmacol 1997, 334: 111-4.
129. Smythies, J. Role of reactive catecholamine species in neurodegeneration: Some basic considerations. In: Mechanisms of degeneration and protection of the dopaminergic system. Segura-Aguilar, J. (Ed.). F.P. Graham Publishing Co: Johnson City, TN, 1999, 181-92.
130. Vairetti, M., Feletti, F., Battaglia, A. et al Haloperidol-induced changes in glutathione and energy metabolism effect of nicergolin. Eur J Pharmacol 1999, 367: 67-72.
131. Sagara, Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998, 71: 1002-12.
132. Cadet, J.L., Lohr, J.B., Jeste, D.V. Tardive dyskinesia and schizophrenic burnout: The possible involvement of cytotoxic free radicals. In: Handbook of Schizophrenia: The neurochemistry and Pharmacology of Schizophrenia. Henn, F.A., DeLisi, L.E. (Eds.). Amsterdam: Elsevier, 1987, 425-38.
133. Richardson, M.A., Haugland, G., Pass, R., Craig, T.J. The prevalence of tardive dyskinesia in a mentally retarded population. Psychopharmacol Bull 1986, 22: 243-9.
134. Ravindranath, V., Reed, D.J. Glutathione depletion and formation of glutathione protein mixed disulfide following exposure of brain mitochondria to oxidative stress. Biochem Biophys Res Commun 1990, 169: 150-8.
135. Nielsen, E.B., Lyon, M. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology 1978, 59: 85-9.
136. Shivakumar, B.R., Ravindranath, V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther 1993, 265: 1137-41.
137. Lohr, J.V., Caligauri, M.R A double-blind placebo controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiat 1996, 57: 167-73.
138. Gupta, S., Mosnik, D., Black, D.W., Berry, S., Masand, P.S. Tardive dyskinesia: Review of treatments past, present, and future. Ann Clin Psychiat 1999, 11: 257-66.
139. Soares, K.V., McGrath, J.J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000, 2: CD000209.
140. Gattaz, W.F., Emirch, A., Behrens, S. Vitamin E attenuates the development of haloperidolinduced dopaminergic hypersensitivity in rats: Possible implication for tardive dyskinesia. J Neural trans 1993, 92: 197-201.
141. Gorrod, J.W., Fang, J. On the metabolism of haloperidol. Xenobiotica 1993, 23: 495-508.
142. Wright, A.M., Bempong, J., Kirby, M.L., Barlow, R.L., Bloomquist, J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release: Possible role of neurotoxicity and tardive dyskinesia. Brain Res 1998, 788: 215-22.
143. Galili-Mosberg, R., Gil-Ad, I., Weizman, A., Melamed, E., Offen, D. Haloperidol-induced neurotoxicity-possible implications for tardive dyskinesia. J Neural Transm 2000, 107: 479-90.
144. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 1994, 268: 380-7.
145. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: Cell culture and neurotransmitter studies. J Pharmacol Exp Ther 1994, 270: 822-30.
146. Filloux, F., Townsend, J. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 1993, 119: 79-88.
147. Eyles, D.W., Pond, S.M., Van der Schyf, C.J., Halliday, G.M. Mitochondrial ultrastructure and density in a primate model of persistent tardive dyskinesia. Life Sci 2000, 66: 1345-50.
148. Bereiter-Hann, J., Voth, M. Dynamics of mitochondria in living cells: Shape changes, dislocations, fusion, and fission of mitochondria. Microscopy Res Tech 1994, 27: 198-219.
149. Roberts, R.C., Gaither, L.A., Gao, X.M., Kashyap, S.M., Tamminga, C.A. Ultrastructural collates of haloperidol-induced oral dyskinesias in the rat striatum. Synapse 1995, 20: 234-43.
150. Jellinger, K. Neuropathologial findings after neuroleptic long-term therapy. In: Neurotoxicology. Roizin, L., Shiraki, H., Grcevic, N. (Eds.). Raven Press: New York 1977, 25-42.
151. Aksel, J.S. Etude clinique et experimentale de l'hibernotherapie. Encephale 1956, 45: 566.
152. Roisin, L., True, C., Knight, M. Structural effects of tranquilizers. Res Publ Assoc Res Nerve Ment Dis 1959, 37: 285-324.
153. Koizumi, J., Shiraishi, H. Glycogen accumulation in astrocytes of the striatum and pallidum of the rabbit following administration of psychotropic drugs. J Electron Microsc 1970, 19: 182-7.
154. Koizumi, J., Shiraishi, H. Synaptic alterations in the rabbit hypothalamus following longterm administration of haloperidol. Folia Psychiat Neurol Jap 1972, 23: 319-26.
155. Koizumi, J., Shiraishi, H. Synaptic changes in the rabbit pallidum following long-term haloperidol administration. Folia Psychiat Neurol Jap 1973, 27: 51-7.
156. Koizumi, J., Shiraishi, H. Synaptic alterations in the hypothalamus of the rabbit following long-term administration of chlorpromazine. Folia Psychiat Neurol Jap 1973, 27: 51-7.
157. Meshul, C.K., Andreassen O.A., Allen, C., Jorgensen, H.A. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmcol 1996, 125: 238-47.
158. Packenberg, H., Fog, R., Nilakantan, B. The long term effect of perpehenazine enanthate on the rat brain. Some metabolic and anatomical observations. Psychopharmacologia 1973, 29: 329-36.
159. Benes, F.M., Paskevich, P.A. Davidson, J., Domesick, V.B. The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res 1985, 329: 265-74.
160. Uranova, N.A., Orlovskaya, D.D., Apel, K., Klintsova, A.J., Haselhorst, U., Schenk, H. Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment. Synapse 1991, 7: 253-9.
161. Kerns, J.M., Sierens, D.K., Kao, L.C., Klawans, H.L., Carvey, P.M. Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin Neuropharmacol 1992, 15: 488-500.
162. Jeste, D.V., Lohr, J.B., Manley, M. Study of neuropathological changes in striatum following 4, 8, or 12 months of treatment with fluphenazine in rats. Psychopharmacol 1992, 116: 89-92.
163. Christensen, E., Moller, J.D., Faurbye, A. Neuropathologial investigation of 28 brains of patients with dyskinesia. Acta Psychiat Scand, 1970, 46: 14-23.
164. Alpert, M., Friedhoff, A., Diamond, F. Use of dopamine receptor number as treatment for tardive dyskinesia. In: Advances in Neurology: Experimental Therapeutics of Movement Disorders. Fahn, S., Calne, D.B., Shoulson, I. (Eds.). 1983, 37: 253-8.
165. Harrison, P.J. The neuropathological effects of antipsychotic drugs. Schrizophr Bull 1999, 40:87-99.
166. Wallace, D.C. Mitochondrial diseases in man and mouse. Science 1999, 283: 1482-8.
167. Klugewicz, D.A., Tracy., K., Lafague, T. et al. Effects of antioxidant treatment on the VCM syndrome. Soc Neuro Abst 1996, 22: 1921.
168. Tarsy, D. Tardive dyskinesia. Curr Treat Opt Neurol 2000, 2: 205-13.
169. Lamberti, J.S., Bellnier, T. Clozapine and tardive dyskinesia. J Nerv Ment Disord 1993, 182: 137-8.
170. Friedman, J.H. Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases. Mov Disord 1994, 9: 321-4.
171. Huang, C.C., Wang, R.H., Hasegawa, A., Alverno, L. Reserpine and N-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol 1981, 73: 359-62.
172. Adler, L.A., Pesalow, E., Rotrosen, J. et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiat 1993, 150: 1405-7.
173. Lohr, J.B., Cadet, J.L., Lohr, M.A. et al. Alphatocopheral in tardive dyskinesia. Lancet 1987, 1: 925-6.
174. Egan, M.F., Hyde, T.M., Albers, G.W. et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiat 1992, 149: 773-7.
175. Shriqui, C.L., Bradwejn, J., Annabel, L. et al. Vitamin E and the treatment of tardive dyskinesia: A double blind placebo-controlled study. Am J Psychiat 1992, 149: 391-3.
176. Dorevitch, A., Kallian, M., Shlafman, M. et al. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiat 1997, 41: 114-6.
177. Feuerstein, G.Z., Shusterman, N.H., Ruffolo Jr., R.R. Carvedilol update IV: Prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drugs of Today 1997, 33: 453-7.
178. Naidu, P.S., Singh, A., Kulkarni, S.K. Possible antioxidant mechanisms in carvedilol reversal of haloperidol-induced orofacial dyskinesia. Br J Pharmacol 2002, 136: 193-200.
179. Rao, M., Gross, G., Strebel, B., Brauning, P., Huber, G., Klosterkotter, J. Serum amino acids, central catecholamines, and hormones in drug-naïve, drug-free, and neuroleptictreated schizophrenic patients and health subjects. Psychiat Res 1990, 34: 243-7.
180. Kim, Y.S., Joo, W.S., Jin, B.K., Cho, Y.H., Baik, H.H., Park, C.W. Melatonin protects 6OHDA-induced neuronal death of nigrostriatal dopaminergic system. Neuroreport 1998, 9: 2387-90.
181. Shamir, E., Barak, Y., Shalman, I. et al. Melatonin treatment for tardive dyskinesia. Arch Gen Psychiat 2001, 58: 1049-52.
182. Bors, W., Heller, W., Michel, C., Saran, M. Flavonoids as antioxidants: Rate constants for reaction with oxygen radicals. Method Enzymol 1994, 234, 420-9.
183. Da Silva, E.L., Piskula, M.K., Yamamoto, N., Moon, J-H., Terao, J. Quercetin metabolites inhibit copper ion-induced lipid peroxidation in rat plasma. FEBS Lett 1998, 430: 405-8.
184. Fiorani, M., De Sanctis, R., Menghinello, P., Cucchiarini, L., Cellini, B., Dacha, M. Quercetin prevents glutathione depletion induced by dehydroascorbic acid in rabbit red blood cells. Free Rad Res 2001, 34: 639-48.
185. Tarsy, D., Kaufman, D., Sethi, K.D. et al. An open label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997, 20: 90-3.
186. Brashear, A., Ambrosius, W.T., Eckert, G.J. et al. Comparison of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998, 13: 158-61.
187. Wang, Y., Turnball, I., Calne, S. et al. Pallidectomy for tardive dyskinesia. Lancet 1997, 349: 777-8.
188. Ondo, W.G., Desaloms, J.M., Jankovic, J. et al. Pallidectomy for generalized dystonia. Mov Disord 1998, 13: 693-8.
189. Wirtshafter, D., Asin, K.E. Haloperidol induces Fos expression in the globus pallidus and substantia nigra of cynomolgus monkeys. Brain Res 1999, 835: 154-61.
190. Cole, D.G., Di Figlia, M. Reserpine increases Fos activity in the rat
191. Fritschym, J.M., Frondoza, C.G., Grzanna, R. Differential effects of reserpine on brain stem catecholaminergic neurons revealed by Fos protein immunoreactivity. Brain Res 1991, 562: 48-56.
192. Hughes, P., Dragunow, M. Induction of immediate early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev 1995, 47: 133-78.
193. Sheng, M., Greenberg, M.E. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 1990, 4: 477-85.
194. Macgibbon, G.A., Lawlor, P.A., Bravo, R., Dragunow, M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Brain Res Mol Brain Res 1994, 23: 21-32.
195. Hussain, N., Flumerfelt, B.A., Rajakumar, N. Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neurosci 2001, 102: 391-9.
196. Ott, M.C., Costain, W.J., Mishra, R.K., Johnson, R.L. L-propyl-1-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)pyrrolidylcarbonyl) amino]-2-oxo-1-pyrrolidine-acetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum. Peptides 2000, 21: 301-8.
197. Post, A., Holsboer, F., Behl, C. Induction of NF-κB activity during haloperidol-induced oxidatie toxicity in clonal hippocampal cells: Suppression of NF-κB and neuroprotection by antioxidants. J Neurosci 1998, 18: 8236-46.
198. Schimidt, K.N., Amstad, P., Cerutti, P., Bauerle, P.A. The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-κB. Chem Biol 1995, 2: 13-22.
199. Sen, R., Baltimore, D. Multiple nuclear factors interact with the immunoglobin enhancer sequences. Cell 1986, 46: 705-6.
200. Baldwin, A.S. The NF-κB and IκB proteins: New discoveries and insight. Ann Rev Immunol 1996, 14: 649-68.
201. Almeida, O.F.X., Conde, G.L., Crochemore, C. et al. Subtle shifts in the ratio between pro and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J 2000, 14: 779-89.
202. Li, P.F., Dietz, R., Von Harsdorf, R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 1999, 18: 6027-36.
203. Ryan, K.M., Ernst, M.K., Rice, N.R., Vousden, K.H. Role of NF-κB in p53-mediated programmed cell death. Nature 2000, 404: 892-7.
204. Qin, Z.H., Chen, R.W., Wang, Y., Nakai, M., Chuang, D.M., Chase, T.N. Nuclear factor κB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor apoptosis. J Neurosci 1999, 19: 4023-33.
205. Post, A., Rucker, M., Ohl, F., Uhr, M., Holsboer, F., Almeida, O.F.X. Mechanisms underlying the protective potential of α-tocopheral (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology 2002, 26: 397-407.
206. Behl, C., Rupprecht, R., Skutella, T., Holsboer, F. Haloperidol-induced cell deathmechanism and protection with vitamin E in vitro. Neuroreport 1995, 7: 360-4.
207. 2-Terminal protein kinase. J Neurochemistry 2000, 75: 2327-34.
208. Gong, C.X., Shaikh, S., Grundke-Iqbal, I., Iqbal, K. Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormality phosphorylated tau by neuroleptics. Brain Res 1996, 741: 95-102.
209. Thore, C.R., Nam, M.J., Bisija, D.W. Immunofluorescent localization of constitutive and inducible prostaglandin H synthase in ovine astroglia. J Comp Neurol 1996, 367: 1-9.
210. Kaufman, M.B., El-Charr, G.M. Bone and tissue changes following prostaglandin therapy in neonates. Ann Pharmacother 1996, 30: 269-74.
211. Adams, J., Collaco-Moraes, Y., de Belleroche, J. Cycoloxygenese-2 induction in cerebral cortex: An intracellular response to synaptic excitation. J Neurochem 1996, 66: 6-13.
212. Yamagata, K., Andreasson, K.I., Kaufmann, W.E., Barnes, C.A., Worley, P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 1993, 11: 371-86.
213. Hastings, T.G. Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J Neurochem 1995, 64: 919-24.
214. Mattammal, M.B., Strong, R., Lakshmi, V.M., Ching, D., Stephenson, A.H. Prostaglandin H synthase-mediated metabolism of dopamine: Implications for parkinson's disease. J Neurochem 1995, 64: 1645-54.
215. Tsai, A., His, L.C., Kulmacz, R.J., Palmer, G., Smith, C.R. Characterization of tyrosyl radicals in ovine prostaglandin H synthse-1 by isotope replacement and site-directed mutagenesis. J Biol Chem 1994, 269: 5085-91.
216. Nogawa, S., Zhang, F., Ross, M.E., Ladecola, C. Cyclooxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997, 8: 2746-55.
217. Hashimoto, K., Minabe, Y., lyo, M. Expression of cyclooxygenase-2 mRNA in rat retrosplenial cortex following administration of phencyclidine. Brain Res 1997, 762: 259-63.
218. Kontos, H.A., Wei, E.P., Povlishock, J.T., Dietrich, W.D., Magiera, C.J., Ellis, E.F. Cerebral arteriolar damage by arachidonic acid and prostaglandin G2. Science 1980, 209:1242-5.
219. Chan, P.H., Fishman, R.A. Transient formation of superoxide radicals in polyunsaturated fatty acid-induced brain swelling. J Neurochem 1980, 35: 1004-7.
220. Chan, P.H. Role of oxidants in ischemic brain damage. Stroke 1996, 27: 1124-9.
221. Elliasson, M.J., Sampei, K., Mandir, A.S. et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 1997, 3: 1089-95.
222. Endres, M., Scott, G., Namura, S. et al. Role of peroxynitrite and neuronal nitric oxide synthase in the activation of poly(ADP-ribose) synthetase in a murine model of cerebral ischemia-reperfusion. Neurosci Lett 1998, 248: 41-4.
223. Bezzi, P., Carmingoto, G., Pasti, L. et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998, 391: 281-5.
224. Ferger, B., Teismann, P., Earl, C.D., Kuschinsky, K., Oertel, W.H. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naun Schm Arch Pharmacol 1999, 360: 256-61.
225. Teismann, P., Ferger, B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001, 39: 167-74.
226. Naidu, P.S., Kulkarni, S.K. Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia. Eur J Pharmacol 2001, 430: 295-8.